PT  - JOURNAL ARTICLE
AU  - Vikas Prasad
AU  - Friedemann Zengerling
AU  - Jochen P. Steinacker
AU  - Christian Bolenz
AU  - Meinrad Beer
AU  - Thomas Wiegel
AU  - Matthias Eiber
AU  - Neil Fleshner
AU  - Ambros J. Beer
TI  - First Experiences with <sup>177</sup>Lu-PSMA Therapy in Combination with Pembrolizumab or After Pretreatment with Olaparib in Single Patients
AID  - 10.2967/jnumed.120.249029
DP  - 2021 Jul 01
TA  - Journal of Nuclear Medicine
PG  - 975--978
VI  - 62
IP  - 7
4099  - http://jnm.snmjournals.org/content/62/7/975.short
4100  - http://jnm.snmjournals.org/content/62/7/975.full
SO  - J Nucl Med2021 Jul 01; 62
AB  - Synergistic effects of immunotherapy with pembrolizumab or drugs targeting DNA damage, such as olaparib, might be used to overcome the limitations of radioligand therapy (RLT) with 177Lu-prostate-specific membrane antigen (PSMA) in metastasized castration-resistant prostate cancer. Here, we present 2 patients receiving such combination or sequential therapies. Methods: RLT was performed at 6- to 8-wk intervals after the patients either exhausted or were considered unfit for all approved conventional treatments. Patient 1 was on pembrolizumab for his squamous cell carcinoma of the skin, whereas patient 2 received RLT sequentially 4 wk after 3 mo of monotherapy with olaparib. Results: Both patients tolerated RLT without any significant hematotoxicity. Patient 2 showed a radiologic and biochemical response, whereas patient 1 achieved prostate-specific antigen stabilization after 3 therapy cycles. Conclusion: These cases indicate that RLT in combination with pembrolizumab or sequentially after olaparib might be well tolerated in single patients.